Effect of a Light Stimulated Footsteps Pathway on Gait in Spastic Children (NCT07289347) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Effect of a Light Stimulated Footsteps Pathway on Gait in Spastic Children
Egypt30 participantsStarted 2025-09-20
Plain-language summary
PURPOSE: The purpose of this study will be investigation of the effect oflight stimulated footsteps pathway on kinematics of gait in spastic diplegic children BACKGROUND: The goal of most therapy procedures for children with spastic cerebral palsy is to increase their walking abilities. Locomotor training usinglight stimulated footsteps pathwayhas been recommended for the rehabilitation of children with cerebral palsy in an effort to improve walking independence and gait speed.
HYPOTHESES: Walking on light stimulated footsteps pathway may not affect kinematics of gait in spastic diplegic children RESEARCH QUESTION: Does walking on light stimulated footsteps pathway have any effect onkinematics of gait in spastic diplegic children?
Who can participate
Age range
4 Years – 8 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age will range between5 and 8 years old.
* They had Grade 1 and 1+ hypertonia according to Modified Ashworth Scale (Bohannon and Smith, 1987)
* Motor Classification System, they were at level I and II (GMFCS)
* They will capable of following commands and comprehend them.
* They will exhibit defective gait kinematics, which can be determined through gait kinematics evaluation.
* All patients who will be enrolled to the study will have their informed consent.
Exclusion Criteria:
* Epilepsy history.
* Taking any anti spastic drugs.
* Both lower limbs had permanent deformity.
* Surgical intervention history.
* Have visual or auditory defects.
* Chest infections or unstable cardiac status.
* Infective skin conditions.
* Markedly high or low blood pressure.
* Individuals with cardiopulmonary conditions.
* Individuals with any pelvic disease.
* Individuals undergoing radiation therapy or chemotherapy.
* Hepatic or pancreatic diseases.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
step length
Timeframe: At baseline and re assessed following 3 months
2
step width
Timeframe: At baseline and re assessed following 3 months
3
spasticity
Timeframe: At baseline and re assessed following 3 months
4
gross motor function
Timeframe: At baseline and re assessed following 3 months